Valuation: Compass Therapeutics, Inc.

Market Cap 393M 345M 317M 296M 558M 37.32B 569M 3.82B 1.48B 18.32B 1.47B 1.44B 63.76B P/E 2026 *
-5x
P/E 2027 * -4.69x
Enterprise Value 243M 213M 196M 183M 345M 23.06B 352M 2.36B 914M 11.32B 911M 891M 39.4B EV / Sales 2026 *
-118x
EV / Sales 2027 * 10.3x
Free-Float
87.55%
Yield 2026 *
-
Yield 2027 * -
1 day+1.61%
1 week+6.28%
Current month+0.46%
1 month+5.77%
3 months-59.63%
6 months-57.45%
Current year-59.03%
1 week 2.02
Extreme 2.015
2.29
1 month 1.88
Extreme 1.88
2.29
Current year 1.61
Extreme 1.61
6.88
1 year 1.61
Extreme 1.61
6.88
3 years 0.76
Extreme 0.765
6.88
5 years 0.76
Extreme 0.765
6.88
10 years 0.76
Extreme 0.765
11
Manager TitleAgeSince
Chief Executive Officer 65 2024-05-27
Director of Finance/CFO 54 2024-12-08
Chief Tech/Sci/R&D Officer 56 2025-12-31
Director TitleAgeSince
Director/Board Member 65 2013-12-31
Director/Board Member 64 2014-12-31
Chairman 61 2014-12-31
Date Insider Type Main position Quantity % Market Cap.
04-28Buy

General Counsel

25,000 0.0139%
04-28Buy

Controller/Auditor

15,000 0.0083%
02-07Tax

Chief Executive Officer

36,687 0.0206%
Change 5-day change 1-year change 3-year change Capi.($)
+1.61%+6.28%-16.03%-29.49% 393M
+3.98%+5.35%+76.06%+135.72% 56.21B
-3.12%+5.11%+71.57%+94.67% 55.38B
+3.88%+7.92%-10.29%-9.92% 23.75B
+2.60%+5.21%+11.88%+429.69% 23.19B
+3.64%+10.54%+39.81%-4.50% 18.14B
+4.11%+8.89%+44.60%-27.73% 16.84B
+2.57%+20.26%+181.98%+355.99% 15.86B
+2.86%+4.55%+25.62%+190.90% 13.56B
+7.20%+10.70%+42.91% - 12.97B
Average +2.92%+7.32%+46.81%+126.15% 23.63B
Weighted average by Cap. +2.13%+6.10%+57.24%+135.57%

Financials

2026 *2027 *
Net sales -2.06M -1.81M -1.66M -1.55M -2.92M -196M -2.98M -20M -7.75M -96M -7.72M -7.56M -334M 25.27M 22.19M 20.42M 19.03M 35.89M 2.4B 36.62M 246M 95.17M 1.18B 94.88M 92.83M 4.1B
Net income -82.44M -72.38M -66.62M -62.08M -117M -7.84B -119M -801M -310M -3.85B -310M -303M -13.39B -89.57M -78.64M -72.39M -67.45M -127M -8.52B -130M -871M -337M -4.18B -336M -329M -14.55B
Net Debt -150M -132M -121M -113M -213M -14.26B -217M -1.46B -565M -7B -563M -551M -24.36B -132M -116M -107M -99.41M -187M -12.55B -191M -1.28B -497M -6.16B -496M -485M -21.44B
Logo Compass Therapeutics, Inc.
Compass Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company. The Company is developing proprietary antibody-based therapeutics to treat multiple human diseases. Its pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. Its lead product candidate, tovecimig, is a bispecific antibody targeting Delta-like ligand 4 (DLL4), a ligand of Notch-1, and vascular endothelial growth factor A (VEGF-A). Its second program, CTX-471, is an agonistic antibody targeting a member of the tumor necrosis factor receptor superfamily member 9 (TNFRSF9), also known as CD-137, a co-stimulatory receptor which is mostly expressed on activated, but not on resting T-cells and NK cells. Its third program, CTX-8371, is a bispecific antibody targeting the programmed cell death protein-1 (PD-1), an inhibitory immune checkpoint receptor, and its ligand PD-L1, two validated immune-oncology targets.
Employees
39
Date Price Change Volume
26-07-02 US$2.195 +0.69% 647,753
26-07-01 US$2.180 -0.46% 2,379,040
26-06-30 US$2.190 +1.39% 3,888,526
26-06-29 US$2.160 +3.85% 2,836,724
26-06-26 US$2.080 +0.48% 7,606,102
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
2.180USD
Average target price
8.500USD
Spread / Average Target
+289.91%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CMPX Stock